Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database

Abstract Background Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key role in the pathogenesis of migraine attacks. The deficiency of CGRP is i...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alexandre O. Gérard, Diane Merino, Elise K. Van Obberghen, Fanny Rocher, Alexandre Destere, Michel Lantéri-Minet, Milou-Daniel Drici
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2022-05-01
Col·lecció:	The Journal of Headache and Pain
Matèries:	CGRP-targeting drugs CGRP receptor antagonist antibody Gepants Migraine CGRP receptor Calcitonin gene-related peptide
Accés en línia:	https://doi.org/10.1186/s10194-022-01424-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!